Blue Dolphin Energy Company reported Q3 2026 net income of $18.9 million, a significant turnaround from a net loss of $4.7 million in the prior year period. The company saw strong operational performance in its refinery segment, generating $23.9 million in refinery operations EBITDA for the quarter. Cash and cash equivalents improved to $40.8 million as of September 30, 2026, driven by $54.4 million in operating cash flow year-to-date.
Term
Q3 2026
“Blue Dolphin delivered another quarter of strong operational and financial performance by capitalizing on market opportunities. We remain focused on safe, reliable operations, margin capture, capital discipline, and value creation while enhancing refining capacity and capabilities.”
Jonathan P. Carroll, Chief Executive Officer of Blue Dolphin Energy Company
Firy Inc. reported Q3 2026 revenue of $31.3 million, a 14% year-over-year increase, driven by 141% growth in its RZR segment. The company narrowed its net loss to $12.5 million and reached a debt-free status following the redemption of $49.7 million in senior secured notes in October. Management highlighted progress in collecting a $730 million judgment against Papaya Gaming and expects positive operating cash flow in 2027.
Term
Q3 2026
“We made substantial progress in Q3 2026, with strong execution across the organization driving accelerating momentum in our transition from turnaround to growth. Revenue grew 14% year over year, led by RZR, which grew 141% and for the first time made up the majority of quarterly revenue.”
Andrew Paradise, FIRY CEO
“Our third quarter results highlight the operating leverage in our business. Our net loss narrowed by $4.9 million year over year, and Adjusted EBITDA excluding litigation expense was a loss of $1.2 million, a $6.2 million improvement from a year ago.”
Research Solutions reported its first quarter fiscal year 2027 results, highlighted by an 11.5% year-over-year increase in B2B Annual Recurring Revenue (ARR) to $16.5 million. While total revenue slightly decreased to $11.9 million due to lower transaction volume, gross margins improved by 300 basis points to 53.6% as the company continues its strategic shift toward higher-margin platform subscription revenue.
Term
Q1 2027
“Our continued investment in innovation is expanding how researchers discover, access, and engage with scientific literature. Recent launches of Article Galaxy and Scite integrations with ChatGPT, Claude, and Microsoft Copilot bring our capabilities directly into the AI-powered workflows researchers increasingly rely on, making it easier to find trusted evidence and access scholarly content.”
Roy W. Olivier, President and CEO
“Platform revenue accounted for 45% of total revenue this quarter, up from 42% a year ago, reflecting our continued transition toward a higher-margin, recurring revenue model. This evolution is strengthening profitability and operating cash flow, enabling us to reinvest in sales capacity and product innovation to accelerate long-term growth.”
MarineMax is pursuing a growth strategy focused on acquisitions, new retail locations, and digital channel expansion, while navigating risks related to manufacturer approvals and integration. The company faces significant international exposure, particularly regarding foreign currency fluctuations and geopolitical tensions involving suppliers in Italy, Poland, Taiwan, and China.
Reliability Inc. reported a net loss of $417,000 for the nine months ended September 30, 2026, compared to a $742,000 loss in the prior year period. A significant balance sheet change occurred in mid-2026 when the company acquired 253,292,210 treasury shares in a non-cash settlement of related-party notes receivable, resulting in a total shareholders' deficit of $200,000.
HealthLynked Corp reported a significant decline in total revenue to $0.83 million for the nine months ended September 30, 2026, compared to $1.76 million in the prior year. The company's net loss widened to $3.33 million, driven largely by a $2.43 million loss on the change in fair value of debt, despite a reduction in total operating expenses.
Insight Molecular Diagnostics Inc. (iMDx) reported a net loss of $19.1 million for the nine months ended September 30, 2026, an improvement from a $27.3 million loss in the prior year period. The company's financial position remains under pressure with a total shareholders' deficit of $24.2 million and a significant contingent consideration liability of $35.3 million.
Beasley Broadcast Group reported a significant net income of $75.4 million for the nine months ended September 30, 2026, primarily driven by a $91.8 million gain on debt restructure. However, the company faced operational challenges, including a $13.1 million FCC license impairment loss and a decline in net revenue from $152.9 million to $129.5 million year-over-year.
Elite Performance Holding Corp. reported zero revenue for the nine months ended September 30, 2026, resulting in a net loss of $784,601. The company's financial position remains strained with a total stockholders' deficit of $3,653,505 and total liabilities of $3,773,501 against only $119,996 in total assets.
Empire Petroleum reported third quarter 2026 financial results with total product revenue of $10.4 million and a net loss of $3.5 million. Operationally, the company advanced its Texas development program in the Fort Trinidad Field, successfully re-entering the Wakefield-Harrison GU B #1 well to a depth of 21,006 feet to evaluate deep productive zones.
Apimeds Pharmaceuticals US, Inc. reported a net loss of $21.6 million for the nine months ended September 30, 2026, compared to a $4.8 million loss in the prior year. The company transitioned its operations, recording its first software development revenue of $2.48 million while managing a significant digital asset portfolio valued at $142.4 million.
Research Solutions reported total revenue of $11.9 million for the quarter ended September 30, 2026, a slight decrease from $12.3 million in the prior year, though net income improved to $765,252. The company continues to transition towards its SaaS Platform business, which saw revenue growth, while Transaction-based revenue declined.
Blue Dolphin Energy Company reported 14,921,968 shares of common stock outstanding as of November 16, 2026. The filing highlights a significant corporate structure where Jonathan Carroll and LEH affiliates own 85.1% of the company, and notes the reunification of BOEM and BSEE into the Marine Minerals Administration effective July 2026.
Onfolio Holdings reported a significant decrease in total revenue to $4.7 million for the nine months ended September 30, 2026, compared to $8.7 million in the prior year. The company experienced a substantial net loss driven by a massive $15.2 million interest expense, contributing to an accumulated deficit of over $42 million.
GT Biopharma reported a net loss of $10.88 million for the nine months ended September 30, 2026, compared to a loss of $22.65 million in the prior year period. The company transitioned to a fully remote model as of July 2024 and maintained a cash balance of $9.92 million as of the reporting date.
Perfect Moment Ltd. reported a net loss of $5.58 million for the six months ended September 30, 2026, a slight improvement from the $5.66 million loss in the prior year period. Total assets increased to $18.27 million from $12.23 million, primarily driven by higher inventory levels and accounts receivable, while the company's shareholders' deficit widened to $3.91 million.
Neuphoria Therapeutics Inc., formerly Bionomics Limited, completed its re-domiciliation from Australia to Delaware in December 2024. As of November 13, 2026, the company reported 5,411,334 shares of common stock outstanding and is currently pursuing a proposed merger with Scancell Holdings plc.
Biotricity Inc. reported revenue of $8.61 million for the six months ended September 30, 2026, a 11% increase year-over-year. Despite achieving positive income from operations of $0.50 million, the company recorded a net loss attributable to common stockholders of $2.02 million due to significant interest expenses and derivative liability adjustments.
Insight Molecular Diagnostics reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center to support its decentralized testing thesis.
Insight Molecular Diagnostics (iMDx) reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center and the appointment of a new transplant sales leader to prepare for commercial launch.
Insight Molecular Diagnostics (iMDx) reported Q3 2026 revenue of $559,000 and provided an update on its FDA de novo submission for GraftAssureDx. The company initiated patient enrollment in its GALACTIC registry study at UCLA Medical Center and appointed a new sales leader to prepare for a potential commercial launch.
Entrepreneur Universe Bright Group Financial Results
Entrepreneur Universe Bright Group reported Q3 2026 revenue of $0.68 million, a decrease from $1.22 million in the prior year period, resulting in a net loss of $0.22 million. The company noted contracting demand in certain consulting lines but saw initial contributions from its newly established Credit Services segment in Hong Kong.
Term
Q3 2026
“Our third quarter results reflected contracting demand in certain consulting service lines, while digital marketing services and our newly established Credit Services segment contributed revenue during the period. We will continue to manage our operations prudently, strengthen our service capabilities and pursue opportunities to expand our revenue base in line with our long-term business objectives.”
Kyntra Bio reported Q3 2026 financial results, highlighting a cash position of $44.1 million and a runway extended into 2028. The company announced the discontinuation of its FG-3246 and FG-3180 programs due to insufficient efficacy, shifting focus toward a planned Phase 3 trial for roxadustat in early 2027. Additionally, the company restructured a royalty financing agreement, reducing its maximum payment obligation by $60 million.
Term
Q3 2026
“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial. We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial.”
Thane Wettig, Chief Executive Officer of Kyntra Bio
374Water Inc. reported a significant revenue increase to $3.47 million for the nine months ended September 30, 2026, compared to $1.90 million in the prior year period. Despite improved gross margins, the company incurred a net loss of $10.53 million due to high operating expenses and a $1.02 million loss on debt extinguishment.
SBIG Holdings, Inc. reported a net income of $3.2 million for the quarter ended September 30, 2026, primarily driven by a $1.7 million gain from discontinued operations and a $1.6 million gain on troubled debt restructuring. The company transferred its operating subsidiary, SpringBig, Inc., in July 2026 and currently has no operating business or revenue as it seeks a strategic transaction.
Acrivon Therapeutics reported Q3 2026 financial results, ending the period with $77.8 million in cash and marketable securities, which is expected to fund operations into Q4 2027. The company highlighted its strategic expansion into immunology and inflammation (I&I) with the acquisition of ACR-525 and provided updates on its clinical pipeline, including upcoming Phase 2b interim data for ACR-368.
Term
Q3 2026
“We have had transformative progress this year, including the strategic expansion into immunology and inflammation and the positive clinical results in tumor types predicted sensitive by AP3 to our internally developed, first-in-class WEE1/PKMYT1 inhibitor ACR-2316, laying the foundation for multiple upcoming value-inflection milestones.”
Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon
For the nine months ended September 30, 2026, FS Credit Real Estate Income Trust reported net income of $98.8 million, a decrease from $129.6 million in the prior year period. Total assets decreased to $11.4 billion from $11.8 billion at year-end 2025, primarily driven by a reduction in mortgage loans held in securitization trusts.
First Breach, Inc. reported a significant increase in net loss to $53.8 million for the nine months ended September 30, 2026, driven by a surge in selling, general, and administrative expenses and stock-based compensation. Despite revenue growth to $0.93 million, the company maintains a negative gross margin and is currently operating as an early-stage, pre-net income entity.
International Land Alliance Inc. reported net revenues of $2.20 million for the nine months ended September 30, 2026, but incurred a net loss of $8.27 million due to high general and administrative expenses and interest costs. The company's total assets remained stable at approximately $32.36 million, while stockholders' equity increased to $8.85 million following significant common stock issuances and debt conversions.
Soluna Holdings, Inc. is a non-accelerated filer and smaller reporting company focused on Bitcoin mining and high-performance computing (HPC) data centers. As of November 12, 2026, the company reported 258,827,640 shares of common stock outstanding and is expanding its services into GPU-as-a-Service and AI-related infrastructure.